|
Match
|
Document |
Document Title |
|
|
US20140242170 |
Corticosteroids for the Treatment of Joint Pain
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing,... |
|
|
US20120141583 |
ALCOHOL RESISTANT DOSAGE FORMS
Opioid controlled release formulation resistant to alcohol extraction of the opioid. |
|
|
US20110020451 |
TAMPER-RESISTANT DOSAGE FORM FOR OXIDATION-SENSITIVE OPIOIDS
Thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, comprising an opioid (A),a free physiologically acceptable acid (B) in an amount of from 0.001 to 5.0 wt.-%,... |
|
|
US20100272807 |
SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into... |
|
|
US20100272795 |
SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into... |
|
|
US20100196481 |
SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS
A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or... |
|
|
US20100151028 |
CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20100151013 |
Gastric acid secretion inhibiting composition
An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on... |
|
|
US20100015230 |
Bone Morphogenetic Protein Compositions
The present invention relates to compositions of bone morphogenetic proteins, particularly solid and liquid formulations of such proteins comprising one or more stabilizing excipients. The... |
|
|
US20090074828 |
POLY(AMINO ACID) TARGETING MOIETIES
The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of... |
|
|
US20080181952 |
Perfusive Organ Hemostasis
Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in... |
|
|
US20080102124 |
Modified Human Growth Hormone
Modified growth hormone polypeptide and uses thereof are provided. |
|
|
US20070202177 |
Antimicrobial Compositions and Methods for Locking Catheters
Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not... |
|
|
US20070104656 |
Matrices Formed of Polymer and Hydrophobic Compounds For Use in Drug Delivery
A lipid or other hydrophobic or amphiphilic compound (collectively referred to herein as “hydrophobic compounds”) is integrated into a polymeric matrix for drug delivery to alter drug release... |
|
|
US20070071824 |
Treatment of mucositis using N-acetylcysteine
This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a... |
|
|
US20070065437 |
Anti-CD3 antibody formulations
This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages of anti-CD3 antibodies, as well as to methods for using such formulations and dosages. |
|
|
US20070049516 |
Use of Insulin for the Treatment of Cartilaginous Disorders
The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the... |
|
|
US20070026073 |
Amorphous efavirenz and the production thereof
Efavirenz compositions of enhanced bioavailability are described that contain efavirenz with at least one solubility-enhancing polymer. Described methods to produce the bioenhanced products... |
|
|
US20070009602 |
Direct drug delivery system based on thermally responsive biopolymers
A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the... |
|
|
US20060165800 |
SHORT DURATION DEPOT FORMULATIONS
Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be... |
|
|
US20060121088 |
Compositions and methods for treating or preventing diseases of body passageways
The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a... |
|
|
US20060034932 |
Anti-angiogenic compositions and methods of use
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic... |
|
|
US20050208137 |
Anti-angiogenic compositions and methods of use
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic... |
|
|
US20050137148 |
Compositions and methods for treating or preventing diseases of body passageways
The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a... |
|
|
US20050048123 |
In situ gelling drug delivery system
The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the... |
|
|
US20050042295 |
Anti-angiogenic compositions and methods of use
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic... |
|
|
US20050003010 |
Injectable cross-linked polymeric preparations and uses thereof
A composition for promoting repair of damaged tissues, being a cross-linked alginate solution, which can be maintained in liquid form indefinitely (under constant conditions) and only gels in... |
|
|
US20130129826 |
TAMPER-RESISTANT ORAL PHARMACEUTICAL DOSAGE FORM COMPRISING OPIOID ANTAGONIST AND/OR AVERSIVE AGENT, POLYALKYLENE OXIDE AND ANIONIC POLYMER
The invention relates to a pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising (i) a pharmacologically active ingredient; (ii) an opioid... |
|
|
US20120021053 |
CONTROLLED RELEASE AND TASTE-MASKING ORAL PHARMACEUTICAL COMPOSITION
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,... |
|
|
US20110165248 |
PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(E-CAPROLACTONE)
The present invention relates to pharmaceutical dosage forms, for example to pharmaceutical dosage forms comprising poly(ε-caprolactone), and processes of manufacture, uses, and methods of... |
|
|
US20110104281 |
METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND
A method for treating pain, particularly non-inflammatory musculoskeletal pain such as myofascial pain or back pain, in a subject comprises administering to the subject a substituted... |
|
|
US20100303912 |
Nanocell Drug Delivery System
Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a... |
|
|
US20100203129 |
CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY
The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective... |
|
|
US20090214652 |
SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS
Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when... |
|
|
US20080299203 |
Solid Pharmaceutical Dosage Formulation
The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor. |
|
|
US20080152690 |
BIODEGRADABLE, ANIONIC POLYMERS DERIVED FROM THE AMINO ACID L-TYROSINE
Polymers with a hydrolytically labile polymer backbones with non-toxic biocompatible diphenolic repeating units having the structure: wherein R9 is an alkyl, aryl or alkylaryl group with up to 18... |
|
|
US20080014274 |
Enhanced stability phenylephrine liquid compositions
An oral, liquid pharmaceutical composition is provided. The composition comprises phenylephrine and substantially aldehyde-free polyethylene glycol. The composition has phenylephrine stability... |
|
|
US20080014237 |
SUSTAINED RELEASE COMPOSITIONS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF
Sustained release compositions containing a physiologically active substance or its salt, hydroxynaphthoic acid or its salt and a lactic acid-glycolic polymer or its salt, wherein the product of... |
|
|
US20070264343 |
METHODS FOR MAKING AND USING PARTICULATE PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE
Pharmaceutical formulations and methods are provided for the sustained delivery of a pharmaceutical agent to a patient by injection. The injectable formulation includes porous microparticles which... |
|
|
US20070259045 |
Alcohol Resistant Dosage Forms
Disclosed in certain embodiments is a controlled release dosage form comprising a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material;... |
|
|
US20060142234 |
Injectable non-aqueous suspension
The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions. |
|
|
US20060141040 |
Injectable non-aqueous suspension
The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions. |
|
|
US20060078617 |
Pharmaceutical compositions for the treatment of cancer
This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and... |
|
|
US20060057210 |
Controlled release oxycodone compositions
A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation... |
|
|
US20060003009 |
Slow release protein polymers
The invention features articles for delivery of a biologically active substance, methods for making such articles, and methods for treating an animal using the articles. |
|
|
US20050249799 |
Polymeric drug delivery system for hydrophobic drugs
An oral delivery system for Class II drugs that have low oral bioavailability due to their insolubility in water and slow dissolution kinetics and method for making such a drug delivery system are... |
|
|
US20050175678 |
Device for the transdermal administration of a rotigotine base
The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(−)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino)-1-naphtol],
containing a matrix... |
|
|
US20050100609 |
Phase-separated polymer coatings
The present invention includes a drug release system. The drug release system comprises a bulk polymer phase and a polymeric drug-enriched phase within the bulk polymer phase. At least one, drug... |
|
|
US20050074496 |
Pharmaceutical compositions and methods relating to fucans
Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis. |
|
|
US20050025809 |
Poly-4-hydroxybutyrate matrices for sustained drug delivery
Biodegradable controlled release systems providing prolonged controlled release of drugs, and methods for the manufacture thereof are disclosed. The systems are formed from a biocompatible,... |